Compare HASI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HASI | COGT |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 2012 | 2018 |
| Metric | HASI | COGT |
|---|---|---|
| Price | $36.93 | $26.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $48.86 | ★ $55.82 |
| AVG Volume (30 Days) | 974.5K | ★ 1.9M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $400,502,000.00 | $7,871,000.00 |
| Revenue This Year | $394.02 | N/A |
| Revenue Next Year | $12.17 | $5,819.52 |
| P/E Ratio | $25.62 | ★ N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $31.07 | $26.36 |
| 52 Week High | $44.13 | $43.73 |
| Indicator | HASI | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 36.08 |
| Support Level | $35.58 | N/A |
| Resistance Level | $37.34 | $37.34 |
| Average True Range (ATR) | 1.18 | 1.77 |
| MACD | -0.23 | -0.36 |
| Stochastic Oscillator | 0.00 | 6.38 |
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.